RxDoctor Payments Data

Geoffrey Tabin, MD

Cornea and External Diseases Specialist · Stanford, CANPI 1912097544

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Alcon at 54.7% of the total. Reporting peaked in 2023 at $723 and has fallen 71.4% since, to $207 in 2025. That places this record below the midpoint for cornea and external diseases specialist clinicians in CA, where the typical reported total is $4,024.

$3,334in general payments, 2019–2025

Across 39 payments — averaging $85.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Carl Zeiss Meditec USA, Inc.$458
  • Tarsus Pharmaceuticals, Inc.$319
  • Carl Zeiss Meditec, Inc.$242
  • Bausch & Lomb Americas Inc.$184
  • Novartis$125
  • plus $184 from 3 others

What the payments were for

  • Food & beverage$3,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,334 in reported general payments places this provider in the 45th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$64,876
Medicare patients
147
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Loteprednol Etabonate11$2,873
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,546
Prednisolone Acetate45$1,829
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha79$959
Doxycycline Hyclate20$868
MoxifloxacinMoxifloxacin Hcl11$568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$62$2,87311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 50 cornea and external diseases specialist providers in California.

Other cornea and external diseases specialist in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →